Orbis Medicines is a spin-off from EPFL with R&D activities at Biopôle in Epalinges, Switzerland. Orbis is supported by leading venture capital firm Novo Holdings and aims to reshape the future of drug discovery. We leverage a new synthesis platform technology to expedite drug discovery for challenging targets in indications with a high degree of unmet need.